News
Search EMA's news announcements
Doxycycline: currently available evidence not supporting link with risk of suicidality
Marketing authorisation holders can now use the platform to report shortages of centrally authorised human medicines.
EMA is advising marketing authorisation holders to submit type I variations for 2024 no later than 30 November 2024.
Leqembi (lecanemab) recommended for treatment of early Alzheimer’s disease
Use of opioid medicines with Mysimba may lead to serious side effects
Regulatory update
Re-examination concludes that benefits outweigh risks in a restricted patient population
Platform technologies enable rapid response to emerging infectious disease threats
Outcomes of the Committee for Veterinary Medicinal Products (CVMP) meeting.
PRAC carried out its broad range of responsibilities for managing the risks associated with medicine use